ACM
SPRB

Altium Capital Management’s Spruce Biosciences SPRB Stock Holding History

Altium Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,816
Closed -$420K – 98
2024
Q2 		$420K Sell
10,816
-4,517
-29% -$242K 0.17% 41
2024
Q1 		$904K Buy
+15,333
New +$3.9M 0.36% 43

Other funds holding SPRB

RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Altium Capital Management's SPRB Position: Q3 2024 in Review

Altium Capital Management sold out of Spruce Biosciences (SPRB) in Q3 2024, closing a stake of 10,816 shares — an estimated $420K sold.

Altium Capital Management first reported a position in SPRB in Q1 2024 and held it in 2 quarters. The position peaked at $904K in Q1 2024. 29 funds tracked by Wall St. Rank hold SPRB as of Q3 2024.

  • Altium Capital Management reported no remaining Spruce Biosciences position as of Q3 2024 after selling out during the quarter.
  • Altium Capital Management sold 10,816 Spruce Biosciences shares in Q3 2024, an estimated $420K.
  • Altium Capital Management first reported a position in Spruce Biosciences in Q1 2024 and held it in 2 quarters.
  • Altium Capital Management's Spruce Biosciences position peaked at $904K in Q1 2024.
  • 29 funds tracked by Wall St. Rank held Spruce Biosciences as of Q3 2024.

Based on Altium Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.